Quidel Corporation  

(Public, NASDAQ:QDEL)   Watch this stock  
Find more results for Ken Brown
20.70
0.00 (0.00%)
Aug 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 18.23 - 29.38
Open     -
Vol / Avg. 0.00/268,584.00
Mkt cap 694.00M
P/E     -
Div/yield     -
EPS -0.11
Shares 33.53M
Beta 0.38
Inst. own 103%
Oct 19, 2015
Q3 2015 Quidel Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 9, 2015
Quidel Corp at Wells Fargo Healthcare Conference - 1:45PM EDT - Add to calendar
Jul 22, 2015
Q2 2015 Quidel Corp Earnings Call - Webcast
Jul 22, 2015
Q2 2015 Quidel Corp Earnings Release
Jun 10, 2015
Quidel Corp at Goldman Sachs Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -25.61% -3.87%
Operating margin -28.17% -5.04%
EBITD margin - 12.44%
Return on average assets -8.10% -1.97%
Return on average equity -14.88% -3.02%
Employees 610 -
CDP Score - -

Address

12544 High Bluff Dr Ste 200
SAN DIEGO, CA 92130-3050
United States - Map
+1-858-5521100 (Phone)
+1-858-4534338 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women's health and gastrointestinal diseases. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors, and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including infectious diseases, women's health, autoimmune diseases, bone health, thyroid diseases and fecal occult blood.

Officers and directors

Kenneth F. Buechler Ph.D. Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Douglas C. Bryant President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Randall J. Steward Chief Financial Officer
Age: 60
Bio & Compensation  - Reuters
Robert Joseph Bujarski J.D. Senior Vice President - Business Development, General Counsel and Corporate Secretary
Age: 46
Bio & Compensation  - Reuters
Werner Kroll Ph.D Senior Vice President,R&D
Age: 58
Bio & Compensation  - Reuters
John D. Tamerius Ph.D. Senior Vice President - Clinical, Regulatory Affairs
Age: 69
Bio & Compensation  - Reuters
Thomas D. Brown Independent Director
Age: 67
Bio & Compensation  - Reuters
Rodney F. Dammeyer Independent Director
Age: 74
Bio & Compensation  - Reuters
Mary Lake Polan M.D., Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Jack W Schuler Independent Director
Age: 74
Bio & Compensation  - Reuters